Survey

DKD Webinar Post Survey

I am a(n)…

[ Required ]

Select...

How many years have you been in practice?

[ Required ]

Select...

What is your practice setting?

[ Required ]

Select...

Number of patients seen per month with DKD

[ Required ]

Select...

Please rate the following:

Degree to which your educational expectations were met

[ Required ]

Select...

Relevance to your practice

[ Required ]

Select...

Effective faculty presenter

[ Required ]

Select...

Overall Presentation

[ Required ]

Select...

Please rate the degree to which Learning Objectives were met.

Identify patients at risk for CKD who should be screened for albuminuria, using UACR, and reduced eGFR to lessen diagnostic delays.

[ Required ]

Select...

Incorporate newer agents such as SGLT-2 inhibitors and MRAs into treatment plans for eligible patients with CKD and T2D.

[ Required ]

Select...

Review new and emerging data regarding the use of MRAs in patients with CKD and DKD.

[ Required ]

Select...

Agree or Disagree?

The presentation was fair and balanced, free of commercial bias.

[ Required ]

Select...

I feel more competent as a result of the presentation.

[ Required ]

Select...

The presentation was scientifically rigorous.

[ Required ]

Select...

The content contributed valuable information that will assist in improving patient outcomes

[ Required ]

Select...

Will you change your practice behaviors as a result of the presentation?

[ Required ]

Select...

What will you change?

[ Required ]

If Other

Because you are likely to make changes to your practice behaviors, you are eligible to qualify for T2P (Translation to Practice) Credit, an additional 2.0 Credits. Please provide your email address below and we will send you a link to a followup survey in six weeks. If you have made changes to your practice behaviors, you will receive those additional two credits.

[ Invalid e-mail address ]

What barriers to change do you foresee?

[ Required ]

If Other

What was your level of knowledge on this subject?

Before the presentation

[ Required ]

Select...

After the presentation

[ Required ]

Select...

Which of the following is true about implementing newer agents for treating T2D and CKD based on a real-world study of ~1.2 million patients in the Veterans Health Administration Database?

[ Required ]

Which of the following agents has NOT been suggested as one of the "Pillars of DKD Management"?

[ Required ]

How confident do you feel in your answer to the previous question?

[ Required ]

Select...

What would you like to learn more about on this subject?